MedTrace Logo

Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer

NCT01138384 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2023-08-04

No results posted yet for this study

Summary

This research is being done because it is not yet known what dose of foretinib in combination with lapatinib can be given safely to patients with breast cancer, nor what type and severity of side effects will result from the combination of the two treatments. This research is also being done because it is not clear if the addition of the new drug foretinib to treatment with lapatinib can offer better results and longer survival than treatment with lapatinib alone.

Conditions

Interventions

DRUG

Foretinib

Daily oral dosing at assigned dose beginning day 3 of cycle 1

DRUG

Lapatinib

Daily oral dosing at assigned dose beginning day 1 cycle 1.

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • NCIC Clinical Trials Group

    lead NETWORK

Principal Investigators

  • Stephen Chia · British Columbia Cancer Agency

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-27
Primary Completion
2014-05-14
Completion
2015-02-13

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01138384 on ClinicalTrials.gov